TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04880018

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsular Tension Ring
Description: Experimental group uses Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd;control group uses Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsular Tension Ring
Description: Experimental group uses Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd;control group uses Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd
Study: NCT01782105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle counseling
Description: Nutritionnal and physical activity counseling and physical activity session group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Evaluation of nutritional and physcial activity habits
Study: NCT01087437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gastrolith calcium
Study: NCT01227746

Intervention type: PROCEDURE
Intervention: Tumor biopsies
Study: NCT03585400

Intervention type: OTHER
Intervention: Observational Study
Description: Observational Study: Not Applicable for Observational Studies
Study: NCT04128670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotape
Description: Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
Study: NCT01399450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone
Description: paliperidone augmenting on ongoing medication
Study: NCT05372224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 4000 IU were administrated once a day for 3 months.
Study: NCT01812200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran, Ticagrelor, ASA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban, Ticagrelor, ASA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon, Ticagrelor, ASA
Study: NCT01303146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhARSA
Description: intravenous infusion 100U/kg every other week for 18 months
Study: NCT04016558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StreamLine
Description: StreamLine is an education/disease management program that focuses on systematic methods to identify and resolve specific blood glucose problems, primarily through changes in carbohydrate consumption, and use of basal and bolus insulin. Participants will attend a brief, four-hour meeting with a Certified Diabetes Educator (CDE) and, using standardized blood glucose data, will learn how to employ a five-point blood glucose management system to identify and resolve blood glucose problems (e.g., excursions, lows) that have the greatest HbA1c or hypoglycemic impacts.~Participants will then meet individually (30 minutes) with their CDE to review their blood glucose data, identify a specific blood glucose problem, and use the five-point program to create a plan to address the problem. Four additional individual meetings (30 minutes) will occur at approximately two to three-week intervals to best support individualized and participant-tailored management-change efforts.
Study: NCT01429454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Long Chain Fatty Acid
Description: : The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
Study: NCT01481974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.~Treatment phase activities include:~• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design.
Study: NCT03444415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interviewing in groups
Description: Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits
Study: NCT04412005

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00403494

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive matching oral Placebo twice daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride
Description: Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
Study: NCT03851094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellth app
Description: The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
Study: NCT04121741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Singing with Music Therapist
Description: Music therapy sessions will begin with vocal and breathing warm-up exercises for about 10 minutes. The Music Therapist will play the songs (chosen from a list by the subject) to sing along to and will alter the characteristics of the music (volume, tempo, level of support) to ensure a successful experience for subjects and motivate them to put forth more effort into singing the song. The music therapist will continue to coach throughout the 30-minute session, reminding subjects of strategies practiced and how to implement those strategies while singing. Music therapy sessions will be led by Erica Flores, MT-BC, WMTR, Owner of Healing Harmonies Music Therapy, or a member of her team. Erica and her team of MTs were trained in Neurological Music Therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Singing with Guided Video
Description: The videos will include a vocal warm-up (10 minutes long). The subject will then have the option to select and sing two songs (10 minutes each), with offerings in four music genres including Folk, Pop, Country, and a Hymn. Each piece will vary in tempo, melodic contour, and rhythm. The total duration of singing via this format will be 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Arm
Description: 30 minute rest period, no singing will take place during this arm. During this rest period a member of the study team will assist the subject in a hearing test using headphones, a tablet, and a trumpet app. This is done to asses the current hearing level of the subject.
Study: NCT01271244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20mg daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20mg daily for 12 weeks
Study: NCT00986752

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting (Smart Stent)
Description: Nitinol stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting (Smart Stent)
Description: Nitinol stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting after PEB (Smart Stent, Invatec)
Description: Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atherectomy (SilverHawk device)
Description: Atherectomy
Study: NCT03246750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-MAD chemotherapy
Description: B-MAD chemotherapy
Study: NCT03490032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-PSMA-R2
Description: radio-labelled PSMA ligand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-PSMA-R2
Description: radio-labelled PSMA ligand

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-PSMA-R2
Description: radio-labelled PSMA ligand
Study: NCT00253266

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine up to 200 mg/d for four weeks
Study: NCT01040312

Intervention type: DRUG
Intervention: CPT-11
Description: CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.

Intervention type: DRUG
Intervention: Platinum analogues
Description: Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
Study: NCT04016558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TunedIn
Description: TunedIn utilizes emotion regulation-based strategies to help participants observe that how they feel affects what they do regarding diabetes management. Participants will attend two highly interactive group workshops (6 hours followed by 2 hours) facilitated by a psychologist or social worker experienced in diabetes. Each will identify and discuss common emotional responses related to blood glucose management (e.g., over-reacting, avoiding, and lack of mindfulness).~Between the two workshops (two weeks), participants will complete a feeling log to document feelings, situation/context, and resolution around specific management events. Two individual meetings with the interventionist (30 minutes) will allow participants to identify and address a specific diabetes distress-related problem. Four web-based video group meetings (60 minutes, monthly) will continue to support participants over time.
Study: NCT00416975

Intervention type: OTHER
Group type: OTHER
Intervention: counseling intervention
Description: Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.

Intervention type: OTHER
Group type: OTHER
Intervention: educational intervention
Description: Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: evaluation of cancer risk factors
Description: Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
Study: NCT04463394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin administered intravenously
Study: NCT04016558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FixIt
Description: FixIt combines components of StreamLine and TunedIn to allow participants to explore feelings and expectations alongside the identification of problematic blood glucose patterns. StreamLine will be co-facilitated by a psychologist/social worker experienced in diabetes and a CDE. Participants will attend two group workshops (six hours followed by four hours), separated by two weeks.~Between the two workshops, participants will record their blood glucose data and keep a parallel feeling log to provide context. Four individual meetings with an interventionist (30 minutes) will allow participants to identify and address a specific blood glucose problem and create a plan to address it. Full discussion of diabetes distress-related aspects of the plan will take place to enhance mindfulness and identify typical emotion regulation strategies to ease problem resolution. Three web-based video group meetings (60 minutes, monthly) will continue to support participants over time.
Study: NCT01101971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic exam video tutorial
Description: Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
Study: NCT02526823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP/CHOPE or ABVD chemotherapy regimen
Description: R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CDOP/CDOPE or DBVD chemotherapy regimen
Description: R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；
Study: NCT02852395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-48816274
Description: Oral dose; dose range of 5 mg up to 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-48816274
Description: Oral dose; dose range of 5 mg up to 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-48816274
Description: Oral dose; dose range of 5 mg up to 250 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose; appearance matched to JNJ-48816274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose; appearance matched to JNJ-48816274
Study: NCT03395704

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection, USP, or equivalent
Study: NCT03152175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: 1mg / kg of propranolol hydrochloride, oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1mg / kg of matched placebo, oral capsule
Study: NCT02679430

Intervention type: DEVICE
Group type: OTHER
Intervention: Prostate Arterial Embolization
Description: The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
Study: NCT02852395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose; appearance matched to JNJ-48816274
Study: NCT02131376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-renorrhaphy
Description: The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renorrhaphy
Description: After tumor resection the patient will have both a deep and cortical layer reconstruction
Study: NCT00513474

Intervention type: DRUG
Group type: OTHER
Intervention: busulfan
Description: Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion

Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporin-A
Description: Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporin-A
Description: Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
Study: NCT03604809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OT Guided Cognitive Interventions
Description: RASS is defined as the level of sedation and agitation of a patient. Cognitive interventions are evidence based strategies that enhance the cognition of patients and include memory training using visual imagery; metacognitive training using self-awareness and self-regulation approaches for recovery of executive functioning; and neuropsychological rehabilitation to help improve cognitive and functional deficits. Interventions will be adjusted according to the RASS score. Cognitive interventions include discussion of patient status and education of family around reorientation, cognitive screening and graded exercises according to patient ability. The deepest levels of sedation and highest levels of agitation will be included in the intervention arm.~Interventions will be provided by the Occupational Therapist; Monday to Friday, BID, 20 minutes per session, for the duration of ICU admission.
Study: NCT00606216

Intervention type: PROCEDURE
Intervention: MRI and cognitive evaluation
Description: Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.

Intervention type: PROCEDURE
Intervention: MRI and cognitive evaluation
Description: Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).

Intervention type: PROCEDURE
Intervention: brain MRI study and a brief neuropsychological evaluation
Description: A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls